AEQUS (AEQUS)
Active threads
Aequs shares plunge 19% as Q2 net loss doubles
Aequs shares fell about 18-19% after its Q2 net loss widened and the consumer EBITDA breakeven timeline was delayed. Management is pinning hopes on aerospace growth and has kept FY27 capex at ₹500-550 crore.
Aequs eyes aerospace, consumer growth
Karnataka-based precision and product manufacturing company Aequs is banking on strong demand from its aerospace business and improving performance in its consumer segment to power its next phase of growth. Backed by a record $1 billion aerospace order book, the company expects sustained momentum while targeting EBITDA break-even in its consumer business by the fourth quarter of FY27. Aravind Melligeri, Executive Chairman & CEO of Aequs, said, “Both aerospace and consumer had a good quarter.
Aequs Q2 loss narrows to ₹52.2 crore as order book hits $1.1 billion
Precision engineering company Aequs reported a consolidated net loss of ₹52.2 crore in the September quarter (Q2 FY27), marginally lower than the ₹53.2 crore loss in the preceding quarter. Higher depreciation and finance costs largely offset an increase in EBITDA. The net loss for the first half of FY27 stood at ₹105.4 crore, compared with ₹16.7 crore a year earlier.
Aequs Q2 loss widens to ₹52 crore despite 45% revenue growth
Aequs Q2 results: Loss widens to ₹52 crore despite 45% revenue growth - Published OnOct 26, 2026 | 16:56 IST - Last Updated OnOct 26, 2026 | 16:56 IST Strong aerospace order book growth and long-term contracts are being offset by widening losses in the consumer segment due to slower volume ramp-ups and supply chain hurdles. Promoters are stepping in with a substantial capital infusion to fund expansion. How will leadership accelerate consumer brea...
Aequs promoter group to inject ₹650cr via convertible warrants
Aequs's promoter group has committed a ₹650 crore capital infusion into the company through convertible warrants. The board has approved the equity infusion, which is earmarked for capacity expansion. The deal now moves toward execution, pending shareholder and regulatory approvals.
Intelligence feed
No articles in the last 24 hours.